Search Results - Kochenkov, Dmitry

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
    Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models

    Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models by Tsimafeyeu, Ilya, Ludes-Meyers, John, Stepanova, Evgenia, Daeyaert, Frits, Kochenkov, Dmitry, Joose, Jean-Baptiste, Solomko, Eliso, Van Akene, Koen, Peretolchina, Nina, Yin, Wei, Ryabaya, Oxana, Byakhov, Mikhail, Tjulandin, Sergei

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies

    Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies by Tyulyandina, Alexandra, Harrison, Daniel, Yin, Wei, Stepanova, Evgenia, Kochenkov, Dmitry, Solomko, Eliso, Peretolchina, Nina, Daeyaert, Frits, Joos, Jean-Baptiste, Van Aken, Koen, Byakhov, Mikhail, Gavrilova, Evgenia, Tjulandin, Sergei, Tsimafeyeu, Ilya

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Abstract 1737: Allosteric FGFR2 inhibitor RPT835 impacts on tumor growth and neovascularization

    Abstract 1737: Allosteric FGFR2 inhibitor RPT835 impacts on tumor growth and neovascularization by Tsimafeyeu, Ilya, Stepanova, Evgenia, Solomko, Eliso, Kochenkov, Dmitry, Peretolchina, Nina, Ryabaya, Oxana, Byakhov, Mikhail, Tjulandin, Sergey

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: